ロード中...
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
There are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxicity profile. Oral ponatinib (Iclusig(®)) is a third...
保存先:
| 出版年: | Ther Adv Hematol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6399752/ https://ncbi.nlm.nih.gov/pubmed/30854182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719826444 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|